Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry Lexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, ...

Roche has reported early-stage clinical ... which is a consideration with some drugs in the oral GLP-1 class. For example, Novo Nordisk's oral formulation of semaglutide for diabetes – Rybelsus ...

Earlier this month, the FDA put out a statement saying that it, too, was concerned about patients and healthcare professionals turning to unapproved versions of GLP-1 drugs as an option for weight ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...

Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging.

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

US stocks plunged following Trump's comments, with the S&P 500 ( ^GSPC) closing Monday's session down 2.4%, the tech-focused Nasdaq ( ^IXIC) sliding 2.6% and the Dow Jones Industrial Average ( ^DJI) ...